CN113171452A - Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application - Google Patents
Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application Download PDFInfo
- Publication number
- CN113171452A CN113171452A CN202110256221.5A CN202110256221A CN113171452A CN 113171452 A CN113171452 A CN 113171452A CN 202110256221 A CN202110256221 A CN 202110256221A CN 113171452 A CN113171452 A CN 113171452A
- Authority
- CN
- China
- Prior art keywords
- nano
- drug
- homogeneous
- preparation
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/002—Magnetotherapy in combination with another treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Abstract
The invention discloses a nano-drug iodized oil homogeneous phase preparation and a preparation method and application thereof. The nano-drug-iodized oil homogeneous preparation is a homogeneous preparation formed by uniformly dispersing a functional nano-drug in an iodized oil injection by using supercritical carbon dioxide, wherein the concentration of the functional nano-drug in the iodized oil is 0.1-20 mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface. The nano-drug-iodized oil homogeneous preparation has better dispersibility, and the nano-drug can be stably dispersed in the iodized oil without coagulation when being stored for a long time. After the nano-drug is introduced into the tumor region, the combined effect of the embolism treatment and the exogenous excitation heat radiation treatment can be realized.
Description
Technical Field
The invention relates to a nano-drug iodized oil homogeneous preparation, a preparation method thereof and application thereof in liver cancer embolism/thermal radiation combined treatment medicaments or embolization agents.
Background
In recent years, nanotechnology has become widely recognized by the public, and its special properties have enabled applications in still more various disciplines. Meanwhile, the nano material is not only applied to a drug delivery system, but also widely applied to biological diagnosis and nano medical treatment due to excellent optical, electrical, magnetic, acoustic and other properties. At present, a plurality of nano-drugs are applied to clinical diagnosis and treatment and achieve better effects. However, the existing nano-drugs have the problems of low concentration of focus areas, in vivo toxicity, easy elimination by the immune system and the like. Therefore, a reasonable, efficient and safe nano-drug administration route is a scientific problem which needs to be solved urgently.
Under the imaging means, the means of introducing the medicament into the focus area through the catheter can realize the high-efficiency enrichment effect of the medicament. Furthermore, hepatic artery chemoembolization (TACE) is an important means for treating liver cancer. Iodophor oil (iodized oil) is widely used in TACE treatment of liver cancer due to its good tumor-selective deposition effect. The effective delivery of the nano-drug is realized while the iodized oil is used for embolism, and the synergy of TACE treatment and the nano-drug can be realized, so that the effect of the synergy of the TACE treatment and the nano-drug is realizedNow the treatment effect of the tumor is enhanced. In 1994, Mitsumori et al dispersed dextran-modified magnetic nanoparticles in iodized oil to obtain magnetofluid emulsion, and after intervention of mixture embolization agent into tumor, combined therapeutic effect of embolization and magnetothermal was achieved (Mitsumori M, Hiraoka M, Shibata T, et al]International journal of hyperthermia,1994,10(6): 785-. It has also been reported that Wangjianhua project group utilizes ultrasonic generator to convert Fe3O4The mixture prepared by dispersing the nano particles into the iodized oil retains Fe3O4The performance of the nanoparticles as an MRI contrast agent, and finally the iodized oil embolism heat treatment strategy realizes the treatment effect of average tumor shrinkage of 8.1% after 14 days on a VX2 rabbit in-situ liver cancer model. The iodized oil is a slow deposition process in a tumor area, and the treatment effect can be well realized only by carrying out exogenous excited thermal radiation treatment after the iodized oil is deposited on the capillary vessels.
At present, the nano-drug is dispersed in the iodized oil through ultrasonic mixing to obtain an emulsion and a suspension, but heterogeneous coarse dispersion systems of the type are unstable in thermodynamics and kinetics, and after long-time embolism, the phenomenon that Brownian motion cannot be overcome when particles are large, the particles are subjected to gravity settling to generate a tendency of coalescence so as to reduce surface free energy, and then the particles are not dispersed. According to Stoke's law, the sedimentation velocity is in direct proportion to the radius of the particles and is in inverse proportion to the viscosity of the iodized oil, the overhigh viscosity of the iodized oil is not beneficial to the action of the medicine, the requirement on the shape of the particles for reducing sedimentation is higher, and the performance of the nano medicine or the dispersion medium is probably influenced by adding a deflocculant and the like, so that the dispersion medium cannot be continuously utilized. Therefore, the emulsion and suspension prepared by the prior art are easy to settle, and are not beneficial to the stimulation treatment after long-time embolism.
Disclosure of Invention
The invention aims to overcome the defects of the prior art, provides a nano-drug iodized oil homogeneous preparation, a preparation method thereof and application thereof in liver cancer embolism/heat radiation combined treatment medicaments or embolization agents, solves the problem that long-time embolism is not beneficial to heat radiation combined treatment in the background art, and also solves the problem of continuous utilization of iodized oil.
One of the technical schemes adopted by the invention for solving the technical problems is as follows: provides a nano-drug-iodized oil homogeneous preparation, which is a homogeneous preparation formed by uniformly dispersing a functional nano-drug in an iodized oil injection by using supercritical carbon dioxide, wherein the concentration of the functional nano-drug in the iodized oil is 0.1-20 mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface.
In a preferred embodiment of the present invention, the particle size of the functional nano-drug is 10 to 500 nm.
In a preferred embodiment of the present invention, the functional nano-drug with magnetocaloric properties is Fe3O4、MnFe2O4、Fe2O3One kind of (1).
In a preferred embodiment of the present invention, the functional nano-drug with photo-thermal properties is one of AuNPs, AgNPs, PtNPs, graphene nanoplatelets, and carbon nanotubes.
In a preferred embodiment of the present invention, the functional nano-drug is one of nanospheres, nanorods, nanosheets and nanotubes.
In a preferred embodiment of the present invention, the specific gravity of the oleic acid or oleylamine in the functional nano-drug is 2 to 20 wt%.
In a preferred embodiment of the present invention, the iodine oil injection is an iodine oil injection containing 37.0-41.0% iodine.
The second technical scheme adopted by the invention for solving the technical problems is as follows: provides a method for preparing a Nano-drug-iodized oil homogeneous phase preparation, namely a hyperstable homogeneous phase Nano-iodized oil formulation technology (SHIFT-Nano), which comprises the following steps:
1) adding the iodine oil injection and the functional nano-drugs into a high-pressure reaction kettle;
2) injecting carbon dioxide into the high-pressure reaction kettle, pressurizing to 10-20 Mpa to form a supercritical environment, and continuously stirring for 1-2 hours;
3) after decompression, the nano-drug iodized oil homogeneous embolic agent is collected from the reaction kettle.
In a preferred embodiment of the present invention, in the step 1), the functional nano-drug is surface-modified by using oleate through pyrolysis or by using oleic acid as an additive solvent.
The third technical scheme adopted by the invention for solving the technical problems is as follows: provides an application of a nano-drug-iodized oil homogeneous preparation in a liver cancer embolism/heat radiation combined treatment medicament or an embolic agent.
Compared with the background technology, the technical scheme has the following advantages:
1. the invention carries out deep research on the delivery of Nano-drugs and provides a formula technology (SHIFT-Nano) of ultra-stable homogeneous Nano-iodine oil, the Nano-drugs are dispersed into the iodine oil by utilizing the supercritical carbon dioxide mixing preparation technology to obtain a homogeneous preparation, and compared with the existing heterogeneous preparations such as emulsion or suspension, the suppository prepared by the invention can not generate coagulation after standing for a long time; the homogeneous preparation is administrated to the tumor area in an intervention mode, so that the effective embolism treatment effect of the iodized oil can be realized, and the nano-drug is retained in the tumor tissue for a long time, so that the synergistic effect of thermal radiation treatment is realized under the condition of external excitation;
2. according to the invention, oleylamine or oleic acid is adopted to modify the functional nano-drug, so that the dispersion of nano-particles in an oil phase is effectively improved, the specific gravity of the oleic acid or oleylamine is 2-20%, if the specific gravity of the oleic acid or oleylamine is lower than 2%, the dispersion effect of the nano-drug in the oil phase is not ideal, and if the specific gravity of the oleic acid or oleylamine is higher than 20%, the effective ratio of the nano-drug is less adverse to the treatment effect of the nano-drug;
3. the functional nano-drug is one of nanospheres, nanorods, nanosheets and nanotubes, has less requirements on the particles of the nano-drug and is easy to realize;
4. the photothermal and magnetocaloric therapeutic properties of the Nano-drug of the invention are not affected after SHIFT-Nano operation, and the viscosity, solubility and diffusivity of the iodized oil are not obviously affected, so that the Nano-drug can be continuously applied to the embolization treatment of liver cancer.
Drawings
FIG. 1 is a flow chart of a process for preparing a Nano-drug, namely an iodized oil homogeneous embolic agent by a SHIFT-Nano method;
FIG. 2 is a flow chart of the application of the nano-drug-iodized oil homogeneous embolic agent in the combined treatment of embolism;
FIG. 3 iodized oil (a), Fe3O4Iodized oil homogeneous embolic agent (b) and Fe3O4-change over time of the iodine oil suspension (b);
FIG. 4 iodine oil and Fe3O4-iodonium oil homogeneous embolic agent viscosity measurement;
FIG. 5 Water, iodized oil, Fe3O4Aqueous solution and Fe3O4Change in temperature of the iodized oil homogeneous embolic agent under an alternating magnetic field (10kA/m,300 kHz).
Detailed Description
The invention will be more clearly illustrated by the following specific examples:
in the invention, through further research on the performance of the iodized oil, a technology for dispersing the Nano-drug with the surface modified by oleic acid or oleylamine into the iodized oil, which is hereinafter referred to as a ultrastable homogeneous Nano-iodized oil formula technology (SHIFT-Nano), is designed. The technology can disperse the nano-drug in the iodized oil for a long time, and simultaneously, the performance of the nano-drug cannot be influenced in the process. The iodized oil and the nano-drug can be embolized in the tumor region by means of interventional administration, so that embolization and nano-drug-based synergistic treatment are realized.
Example 1
1. This example is Fe3O4-a process for the preparation of a homogeneous formulation of iodonium oil comprising the following steps (figure 1):
(a) first, iron oleate complex is prepared by pretreatment, 5.4g FeCl3·6H2O and 18.3g of sodium oleate were added to a mixed solution of 40mL of ethanol, 30mL of water and 70mL of hexane and reacted at 70 ℃ for 4 hours, thereby isolating an iron oleate complex; then adding the iron oleate complex and oleic acid into the 1-octadecene, wherein the addition amounts of the iron oleate complex, the oleic acid and the 1-octadecene are respectively 18g, 2.9g and 100g, and the mixture is stableHeating to 320 ℃ and keeping for 0.5h to obtain brownish black oleic acid surface modified Fe3O4A nanoparticle;
(b) 2mg of Fe are taken3O4Adding the nano particles and 2mL of iodized oil into a reaction kettle, injecting carbon dioxide into the reaction kettle, pressurizing to 20Mpa to form a supercritical environment, and continuously stirring for h;
(c) after depressurization, Fe was collected from the reaction vessel3O4-iodooil homogeneous formulations.
2. Fe prepared in this example3O4-iodine oil homogeneous preparation, oleic acid modified Fe3O4The nanometer particles are uniformly dispersed in an iodized oil medium as a functional nanometer drug, and the embolic agent prepared based on the nanometer particles is applied to liver cancer embolism/heat radiation combined treatment and comprises the following steps:
(a) mixing Fe3O4-introduction of a homogeneous embolic agent in the tumor tissue;
(b) the embolism effect is generated under the action of the iodized oil;
(c) and judging through various physiological indexes, and performing magnetic heat treatment by using an external magnetic heat device when the condition of the magnetic heat treatment is achieved.
Example 2
Example 2 differs from example 1 in that:
1. this example provides a method for preparing a homogeneous embolic agent of AuNPs-iodized oil, comprising the following steps:
(a) firstly, preparing AuNPs by utilizing chloroauric acid and sodium borohydride, adding the AuNPs and oleylamine which are prepared into ethanol according to the concentration of 2mg/mL and 1mg/mL, and stirring for 6 hours to obtain AuNPs nanoparticles with oleylamine surface modified;
(b) adding 1mg of Fe3O4 nanoparticles and 2mL of iodized oil into a reaction kettle, injecting carbon dioxide into the reaction kettle, pressurizing to 15Mpa to form a supercritical environment, and continuously stirring for 1 h;
(c) after decompression, the AuNPs-iodol homogeneous preparation was collected from the autoclave.
2. The embolization combination therapy based on AuNPs-iodonium oil homogeneous embolization agent comprises the following steps:
(a) introducing AuNPs-iodized oil homogeneous embolic agent into tumor tissues;
(b) the embolism effect is generated under the action of the iodized oil;
(c) the judgment is carried out through various physiological indexes, and when the conditions of radiotherapy treatment are met, the photothermal treatment is carried out by utilizing an external photothermal device.
Then, the Nano-drug-iodized oil homogeneous preparation prepared by the SHIFT-Nano method in the example and the Fe prepared by the traditional ultrasonic treatment for 30min3O4Iodine oil suspension as control, results are as follows:
Fe3O4iodine oil homogeneous embolic agent having specific Fe3O4Longer stability time of iodooil suspensions (figure 3). And, Fe after standing for 14 days3O4The iodized oil homogeneous embolic agent still has better dispersibility. In addition, the process of preparing the Nano-drug-iodized oil homogeneous embolic agent by the SHIFT-Nano method does not influence the viscosity of the iodized oil (figure 4), thereby providing guarantee for subsequent embolic treatment.
Finally, for Fe3O4The magnetocaloric effect of the iodized oil homogeneous embolic agent was investigated. As shown in FIG. 5, Fe3O4Iodine oil homogeneous embolic agent with Fe3O4Aqueous solutions have similar magnetocaloric effects. Thus, Fe produced3O4Lipiodol homogeneous embolization agents enable a combined effect of tumor embolization and magneto-caloric therapy.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. A nano-drug-iodized oil homogeneous preparation is characterized in that: the functional nano-drug is a homogeneous preparation formed by uniformly dispersing the functional nano-drug in an iodine oil injection by using supercritical carbon dioxide, and the concentration of the functional nano-drug in the iodine oil is 0.1-20 mg/mL; the functional nano-drug has magnetocaloric property or photo-thermal property, and is modified with oleic acid or oleylamine on the surface.
2. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the particle size of the functional nano-drug is 10-500 nm.
3. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the functional nano-drug with the magnetocaloric property is Fe3O4、MnFe2O4、Fe2O3One kind of (1).
4. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the functional nano-drug with photo-thermal property is one of AuNPs, AgNPs, PtNPs, graphene nanosheets and carbon nanotubes.
5. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the functional nano-drug is one of nanospheres, nanorods, nanosheets and nanotubes.
6. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the proportion of the oleic acid or the oleylamine in the functional nano-drug is 2-20 wt%.
7. The homogeneous nano medicine-iodine oil preparation as set forth in claim 1, characterized in that: the iodine oil injection is an iodine oil injection containing 37.0-41.0% of iodine.
8. The method for preparing the nano-drug-iodized oil homogeneous preparation according to any one of claims 1 to 7, wherein the method comprises the following steps: the method comprises the following steps:
1) adding the iodine oil injection and the functional nano-drugs into a high-pressure reaction kettle;
2) injecting carbon dioxide into the high-pressure reaction kettle, pressurizing to 10-20 Mpa to form a supercritical environment, and continuously stirring for 1-2 hours;
3) after decompression, the nano-drug iodized oil homogeneous embolic agent is collected from the reaction kettle.
9. The method for preparing the nano-drug-iodized oil homogeneous preparation according to claim 8, wherein the method comprises the following steps: in the step 1), the functional nano-drug is subjected to surface modification by using a method of decomposing oleate at high temperature or using oleic acid as an adding solvent.
10. The use of the nano-drug-iodophor oil homogeneous preparation according to any one of claims 1 to 7 in liver cancer embolization/thermal radiation combination therapy or embolization agents.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110256221.5A CN113171452B (en) | 2021-03-09 | 2021-03-09 | Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110256221.5A CN113171452B (en) | 2021-03-09 | 2021-03-09 | Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113171452A true CN113171452A (en) | 2021-07-27 |
| CN113171452B CN113171452B (en) | 2023-02-03 |
Family
ID=76921919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110256221.5A Active CN113171452B (en) | 2021-03-09 | 2021-03-09 | Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113171452B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952476A (en) * | 2021-10-15 | 2022-01-21 | 厦门大学 | Preparation of medicine-doped homogeneous phase ethanol chemical fusogenic agent |
-
2021
- 2021-03-09 CN CN202110256221.5A patent/CN113171452B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| XIAONING SUN 等: "Characterization of Magnetite/Iodized Oil Magnetic Fluid for Embolization and Hyperthermia Application", 《JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM》 * |
| 王琳 等: "基于超临界流体技术制备药物制剂的研究进展", 《科学通报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952476A (en) * | 2021-10-15 | 2022-01-21 | 厦门大学 | Preparation of medicine-doped homogeneous phase ethanol chemical fusogenic agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113171452B (en) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Iron oxide nanoparticle based contrast agents for magnetic resonance imaging | |
| EP2010152B1 (en) | Magnetic nanoparticles compositions and uses thereof | |
| Zhang et al. | Graphene oxide-BaGdF5 nanocomposites for multi-modal imaging and photothermal therapy | |
| Khademi et al. | Targeted gold nanoparticles enable molecular CT imaging of head and neck cancer: an in vivo study | |
| Lee et al. | Paramagnetic inorganic nanoparticles as T1 MRI contrast agents | |
| Maity et al. | Novel synthesis of superparamagnetic magnetite nanoclusters for biomedical applications | |
| Miao et al. | PEGylated rhenium nanoclusters: A degradable metal photothermal nanoagent for cancer therapy | |
| Zha et al. | Engineering of perfluorooctylbromide polypyrrole nano-/microcapsules for simultaneous contrast enhanced ultrasound imaging and photothermal treatment of cancer | |
| CN104689346B (en) | For tumour MRI/CT imagings and multifunctional nano probe and the application of photo-thermal therapy | |
| Zhang et al. | Green synthesis of sub‐10 nm gadolinium‐based nanoparticles for sparkling kidneys, tumor, and angiogenesis of tumor‐bearing mice in magnetic resonance imaging | |
| CN113171452B (en) | Nanometer medicinal preparation, YOU homogeneous preparation, and its preparation method and application | |
| Qian et al. | Synthesis of urchin-like nickel nanoparticles with enhanced rotating magnetic field-induced cell necrosis and tumor inhibition | |
| Li et al. | Photogenerated electrons from CeO2 via upconversion of excitons to conduction band enhanced photocatalysis for Photo-Therapy of Rheumatoid arthritis | |
| CN111615402A (en) | Nanoparticles for medical or cosmetic applications sequentially exposed to low intensity sound waves | |
| Lin et al. | Size and morphological effect of Au–Fe 3 O 4 heterostructures on magnetic resonance imaging | |
| CN105126113A (en) | Preparation method and application of transferrin modified hollow mesoporous copper sulfide/artesunate nanoparticles | |
| Hu et al. | Special interstitial route can transport nanoparticles to the brain bypassing the blood-brain barrier | |
| Li et al. | Designed formation of Prussian Blue/CuS Janus nanostructure with enhanced NIR-I and NIR-II dual window response for tumor thermotherapy | |
| Rivera et al. | Biocompatible superparamagnetic carriers of chondroitin sulfate | |
| Cai et al. | Exfoliation and in situ functionalization of MoS2 nanosheets for MRI-guided combined low-temperature photothermal therapy and chemotherapy | |
| Wang et al. | Transferrin-conjugated superparamagnetic iron oxide nanoparticles as in vivo magnetic resonance imaging contrast agents | |
| Wang et al. | A multifunctional, highly biocompatible, and double-triggering caramelized nanotheranostic system loaded with Fe3O4 and DOX for combined chemo-photothermal therapy and real-time magnetic resonance imaging monitoring of triple negative breast cancer | |
| CN110538331B (en) | Method for preparing magnetic nano-particles with improved dispersibility and particle uniformity | |
| CN101549161A (en) | Liver, spleen specific positive magnetic nuclear resonance contrast agent and method of preparing the same | |
| CN114015064B (en) | Porphyrin MOF nanosheet with ultrasonic stimulus response, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |